- Guide to PHARMACOLOGY
Abbreviated name: PD-L1
Synonyms: B7 homolog 1 | B7-H1 | PDL1 | programmed death ligand 1
Compound class: Endogenous peptide in human, mouse or rat
Comment: This is one of the ligands for the PD-1 receptor. It is a single-pass type I membrane protein. The PD-L1/PD-1 interaction is an established immune checkpoint. Both the ligand and receptor are targets for novel immuno-oncology therapeutics, as over-expression of either of these proteins is a mechanism used by tumour cells to evade immune detection and destruction. Already the target of approved immunotherapeutics in the form of monoclonal antibodies, small molecules targeting the PD-1/PD-L1 checkpoint are now in development to address the shortcomings associated with the current antibody therapies (including, poor susceptibility rate to single immune checkpoint pathway inhibitors, long half-life of antibodies and association with the development of adverse events, problems connected to the requirement for intravenous infusions) [5,14].
|No information available.|
|Summary of Clinical Use|
|PD-L1 is an important immunopharmacological drug discovery target, as many types of cancer cells express this ligand [4,7,15] as a means of evading immune detection and destruction by T-cell-mediated responses. Three monoclonal antibodies directed against PD-L1 are approved cancer therapeutics. Additional reading:  and .|